Meta‐analysis of B type natriuretic peptide and N‐terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction

  title={Meta‐analysis of B type natriuretic peptide and N‐terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction},
  author={Ben D. Ewald and D Ewald and Ammarin Thakkinstian and John Attia},
  journal={Internal Medicine Journal},
Background:  We set out to review the validity of tests for B type natriuretic peptide (BNP) and N‐terminal pro BNP (NTproBNP) in the diagnosis of clinical heart failure (HF) in primary care and hospital settings and to examine the effect of age. We also examined the accuracy of the test in population screening for left ventricular systolic dysfunction. 

Left Ventricular Ejection Fraction in Addition to N-Terminal Pro–B-Type Natriuretic Peptide for Risk Stratification in the Ambulant Elderly

An assessment of N-terminal pro–B-type natriuretic peptide and echocar-diographic left ventricular ejection fraction in screening for risk of subsequent new-onset HF and CVD in ambulant elderly patients finds that both indicators are independent predictors of adverse cardiovascular outcomes and, in combination, improve risk stratification.

Utility of natriuretic peptide testing in the evaluation and management of acute decompensated heart failure

The addition of BNP and NT-proBNP to usual clinical decision making enhances detection of high-risk patients who need aggressive follow-up and adjustment of treatment.

N-terminal pro-b-type natriuretic peptide and left atrial function in patients with congestive heart failure and severely reduced ejection fraction.

In CHF patients with severely impaired systolic function, NT-pro-BNP levels reflect LA and LV dysfunction, and should prompt studies to investigate the relationship between changes of LA function and NT- pro-BNp levels and their clinical value as prognostic and therapeutic targets in CHF.

Hemoglobin Concentration Influences N‐Terminal Pro B‐Type Natriuretic Peptide Levels in Hospitalized Older Adults with and without Heart Failure

To investigate the relationship between hemoglobin and N‐terminal pro B‐type natriuretic peptide (NT‐proBNP) concentration in hospitalized older adults with or without a diagnosis of heart failure, a large number of subjects were treated for heart failure.

Comprehensive Review of the Relative Clinical Utility of B-Type Natriuretic Peptide and N-Terminal Pro-B-Type Natriuretic Peptide Assays in Cardiovascular Disease

While optimal diagnostic cutpoints for both markers varied depended on age and degree of renal dysfunction, and the clinical application; NT-proBNP had a much more widely variable optimal cutpoint than did BNP, sufficient evidence for clinical utility of both tests exists for other applications of prognosis, screening, and monitoring of heart failure.

The role of b-type natriuretic peptide in heart failure management.

Natriuretic peptide testing in primary care patients

Plasma concentration of B-type-related natriuretic peptides is a marker of either hemodynamic or neurohormonal stress on the heart and has been validated within the diagnostic and prognostic domain in patients with suspected or ascertained heart failure, mostly in the in-hospital setting.

Natriuretic peptide measurement in heart failure

Chris Higgins summarizes the recommendations of 2 new guidance documents on the use of natriuretic peptides in heart failure and provides brief overviews of BNP/NT-proBNP and heart failure.

Natriuretic peptides as indicators of cardiac remodeling in hypertensive patients

Nt-BNP and BNP are useful to discriminate between patients with regard to cardiac remodeling and might be considered a screening tool in order select patients eligible for further examination with UCG examination.



Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure

BNP and NT-proBNP may be equally useful as an aid in the diagnosis of CHF in short of breath patients presenting to the emergency department when compared by logistic regression models.

Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes.

BNP can reliably screen diabetic patients for the presence or absence of left ventricular dysfunction, and in those patients who had a CIE, BNP levels showed a high positive predictive value for the detection of left Ventricular dysfunction.

Utility of N-terminal pro-brain natriuretic peptide for the diagnosis of heart failure.

The results suggest that N-terminal pro-brain natriuretic peptide can be reliably used for the diagnosis of heart failure in an outpatient setting, and this will improve the ability of clinicians to differentiate patients with shortness of breath due to heart failure from those with other causes of shortnesses of breath.

Plasma N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in assessment of acute dyspnea.

Combination of B-type natriuretic peptide levels and non-invasive hemodynamic parameters in diagnosing congestive heart failure in the emergency department.

The authors conclude that, in patients presenting to an emergency department with dyspnea, the addition of impedance cardiography measurements to BNP level measurements will more effectively diagnose congestive heart failure and determine both the type of heart dysfunction and the severity of illness.